Other

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the […]

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Read More »

Isofol presents a clinical development plan for arfolitixorin

By

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program for the drug candidate arfolitixorin. The board and management, together with external experts, have evaluated the available data for arfolitixorin and decided to conduct a clinical phase I/II study to document

Isofol presents a clinical development plan for arfolitixorin Read More »

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

By

GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting Read More »

Scroll to Top